Reform for Raising Prices Following its earlier report about record-breaking increases on drug prices, the NYT today editorializes that Congress should abandon its “deal” with the drug industry, which traded industry support for healthcare reform for $80 B in price cuts, mainly to Medicare and Medicaid. http://www.nytimes.com/2009/11/18/opinion/18wed3.html?emc=tnt&tntemail1=y The industry claims are all those we’ve heard in every other context in which its interest has needed defending–the price of new drug development, meeting FDA’s regulatory demands, etc., etc.. How real was this “deal” ever? Is it time to fuggedaboudit?

Original Source of NYT TO PHARMA–FUGGEDABOUDIT